Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Level Up: Upadacitinib vs Dupilumab in Atopic Dermatitis
NCT05601882Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Nov 2022; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05601882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601882.